Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel.
Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel.
Oncotarget. 2023 Jul 1;14:688-699. doi: 10.18632/oncotarget.28467.
Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. In this study, we show that a derivative of the hormone peptide Tumor Cell Apoptosis Factor (TCApF), Nerofe (dTCApFs), in combination with Doxorubicin (DOX) substantially reduces viability of tumor cells. It was observed that the combination of Nerofe and DOX downregulated KRAS signaling via miR217 upregulation, resulting in enhanced apoptosis of tumor cells. In addition, the combination of Nerofe and DOX also resulted in activation of the immune system against tumor cells, manifested by an increase in the immunostimulatory cytokines IL-2 and IFN-γ as well as the recruitment of NK cells and M1 macrophages to the tumor site.
鼠肉瘤病毒癌基因(RAS)亚家族 KRAS 成员是人类癌症中经常发生突变的癌基因,已在胰腺导管、结直肠和肺腺癌中被鉴定出来。在这项研究中,我们表明,激素肽 Tumor Cell Apoptosis Factor(TCApF)的衍生物 Nerofe(dTCApFs)与阿霉素(DOX)联合使用可显著降低肿瘤细胞的活力。观察到 Nerofe 和 DOX 的联合使用通过 miR217 的上调下调 KRAS 信号通路,导致肿瘤细胞凋亡增强。此外,Nerofe 和 DOX 的联合使用还导致针对肿瘤细胞的免疫系统激活,表现为免疫刺激细胞因子 IL-2 和 IFN-γ 的增加以及 NK 细胞和 M1 巨噬细胞向肿瘤部位的募集。